Saadoun et al. conducted one of the earliest open-label trials on Ld-IL-2 in SLE, demonstrating significant reductions in disease activity scores and improvements in complement levels after a 5-day IL-2 course [15]. This evidence concerns the gene IL2 and systemic lupus erythematosus.